within Pharmacolibrary.Drugs.ATC.H;

model H01AC04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00039333333333333337,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0155,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01AC04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), used as a diagnostic agent to assess growth hormone secretion and has been investigated for the treatment of growth hormone deficiency in children and adults. It is no longer widely marketed or approved for clinical use, having been withdrawn in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Esposito, P, et al., &amp; Veronese, FM (2003). PEGylation of growth hormone-releasing hormone (GRF) analogues. <i>Advanced drug delivery reviews</i> 55(10) 1279–1291. DOI:<a href=\"https://doi.org/10.1016/s0169-409x(03)00109-1\">10.1016/s0169-409x(03)00109-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14499707/\">https://pubmed.ncbi.nlm.nih.gov/14499707</a></p></li><li><p>Wilton, P, et al., &amp; Gunnarsson, R (1993). Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. <i>Acta paediatrica (Oslo, Norway : 1992). Supplement</i> 388 10–15. DOI:<a href=\"https://doi.org/10.1111/j.1651-2227.1993.tb12827.x\">10.1111/j.1651-2227.1993.tb12827.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8329825/\">https://pubmed.ncbi.nlm.nih.gov/8329825</a></p></li><li><p>Soule, S, et al., &amp; Millar, RP (1994). Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. <i>The Journal of clinical endocrinology and metabolism</i> 79(4) 1208–1211. DOI:<a href=\"https://doi.org/10.1210/jcem.79.4.7962295\">10.1210/jcem.79.4.7962295</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7962295/\">https://pubmed.ncbi.nlm.nih.gov/7962295</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01AC04;
